Farage (ATCC® CRL-2630)

Organism: Homo sapiens, human  /  Cell Type: B lymphocyte  /  Tissue: derived from metastatic site: lymph node  /  Disease: non-Hodgkin's B cell lymphoma

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Tissue derived from metastatic site: lymph node
Cell Type B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2  [Cells contain Epstein-Barr virus (EBV)]

Biosafety  classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease non-Hodgkin's B cell lymphoma
Age adult
Gender female
Ethnicity White
Karyotype trisomy of chromosome 11 RefGabay C, et al. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur. J. Immunol. 63: 180-191, 1999. PubMed: 10485273
Derivation
The Farage cell line was adapted to culture in 1990 from a lymph node biopsy of a patient with diffuse large cell non-Hodgkin's lymphoma (DLCL).
Clinical Data
adult
female
White
Antigen Expression
CD10 +/-; CD11a + (LFA-1); CD19 +; CD20 +; CD21 +; CD22 +; CD23 +; CD29 (VLA-4) +; CD38 +; CD39 +; CD40 +; CD44 +; CD54 + (ICAM-1); CD58 + (LFA-3); CD23 -; HLA DR +
Comments
The cells do not express surface or cytoplasmic immunoglobulin.

Exposure to IL-4 augmented the concentrations of CD23, CD54, and CD58 but diminished the expression of CD21, CD22, and CD38. Incubation with IL-4 for 6 to 8 days led to increased expression of CD11a, CD39, CD40, and to disappearance of CD21 and CD38.

Exposure of Farage cells to phorbol 12-myristate 13-acetate (PMA) down-regulated CD21 and CD23 expression.

They do not express the terminal deoxynucleotydyl transferase gene (TdT), nor the recombination activating genes RAG-1 and RAG-2, known as markers of the pre-B cell stage. These results show that Farage represents a mature B-cell rather than a pre-B cell.

The cells are positive for Epstein-Barr virus (EBV).
mature B cell
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
Subculturing Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 3 - 5 x 105 viable cells/mL. Maintain cell density between 3 x 105 and 3 x 106 viable cells/mL.

Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density).
Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37°C
STR Profile
Amelogenin: X
CSF1PO: 11,12
D13S317: 11,13
D16S539: 11,12
D5S818: 12
D7S820: 12
THO1: 8,9
TPOX: 9
vWA: 14,15
Population Doubling Time 24 to 36 hrs
Name of Depositor H Ben-Bassat
Year of Origin 1990
References

Baruch M, et al. Molecular characterization of an unusual non-Hodgkin's B-lymphoma cell line ("Farage") lacking the ability to produce immunoglobulin polypeptide chains. Leuk. Lymphoma 21: 485-495, 1996. PubMed: 9172815

Gabay C, et al. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur. J. Immunol. 63: 180-191, 1999. PubMed: 10485273

Shubinsky G, et al. The effect of IL-4 on the phenotype of a human B-cell lymphoma line (Farage) lacking immunoglobulin expression. Immunol. Lett. 36: 37-42, 1993. PubMed: 8344715

Shubinsky G, et al. Pathways controlling the expression of surface CD21 (CR2) and CD23 (Fc(epsilon)IIR) proteins in human malignant B cells. Leuk. Lymphoma 25: 521-530, 1997. PubMed: 9250823

Shubinsky G, Schlesinger M. Kinetics of the pleiotropic effect of interleukin 4 on the surface properties of human B-lymphoma cells. Leuk. Lymphoma 15: 333-340, 1994. PubMed: 7866283

Shubinsky G. The mechanism of interleukin 4-induced down-regulation of CD38 on human B cells. Cell. Immunol. 10: 87-95, 1996. PubMed: 8871604

Gabay C, et al. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur. J. Immunol. 63: 180-191, 1999. PubMed: 10485273

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Baruch M, et al. Molecular characterization of an unusual non-Hodgkin's B-lymphoma cell line ("Farage") lacking the ability to produce immunoglobulin polypeptide chains. Leuk. Lymphoma 21: 485-495, 1996. PubMed: 9172815

Gabay C, et al. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur. J. Immunol. 63: 180-191, 1999. PubMed: 10485273

Shubinsky G, et al. The effect of IL-4 on the phenotype of a human B-cell lymphoma line (Farage) lacking immunoglobulin expression. Immunol. Lett. 36: 37-42, 1993. PubMed: 8344715

Shubinsky G, et al. Pathways controlling the expression of surface CD21 (CR2) and CD23 (Fc(epsilon)IIR) proteins in human malignant B cells. Leuk. Lymphoma 25: 521-530, 1997. PubMed: 9250823

Shubinsky G, Schlesinger M. Kinetics of the pleiotropic effect of interleukin 4 on the surface properties of human B-lymphoma cells. Leuk. Lymphoma 15: 333-340, 1994. PubMed: 7866283

Shubinsky G. The mechanism of interleukin 4-induced down-regulation of CD38 on human B cells. Cell. Immunol. 10: 87-95, 1996. PubMed: 8871604

Gabay C, et al. Somatic mutations and intraclonal variations in the rearranged Vkappa genes of B-non-Hodgkin's lymphoma cell lines. Eur. J. Immunol. 63: 180-191, 1999. PubMed: 10485273